Cambridge Nucleomics appoints diagnostics veteran Dr Anthony Cooke as independent chairman

Cambridge Nucleomics is delighted to announce the appointment of Dr Anthony (Tony) Cooke as Independent chairman of the board. Dr Cooke brings over 40 years' in vitro diagnostic (IVD) development and commercialisation experience to the company. His extensive career spans the entire product lifecycle, from R&D and manufacturing to complex regulatory compliance and laboratory operations. He currently serves as CEO of Procyon Diagnostics and previously Cambridge Clinical Laboratories, as well as Development and Manufacturing Director at Lab21 Group (now Novacyt SA).

For the past five years, Dr Cooke has been at the forefront of introducing novel early-detection cancer tests from global manufacturers into both the UK private healthcare market and the NHS. His commitment to improving early cancer detection, demonstrated through his involvement with initiatives such as PancRISK, perfectly aligns with our vision for the Cambridge Nucleomics platform.

With a strong track record of guiding deep tech life science start-ups to success, Dr Cooke’s deep understanding of diagnostic regulatory pathways and commercialisation will be invaluable as we advance our lead sepsis programme and explore our platform's immense potential in precision medicine.